The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
下载
收藏
页数：8
相关论文
共 50 条
  • [41] Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short, Nicholas James
    Keating, Michael J.
    Wierda, William G.
    Faderl, Stefan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Smith, Susan C.
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] The treatment of complicated and high risk chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide and rituximab (FCR).
    Donthireddy, V
    Shurafa, MS
    Saleh, M
    Kamboj, G
    Wang, D
    Janakiraman, N
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [43] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
    Grifi, Fatiha
    Bougherira, Soraya
    Djenouni, Amel
    LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
  • [44] Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
    Mandrik, Olena
    Ramos, Saac Corro
    Knies, Saskia
    Al, Maiwenn
    Severens, Johan L.
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 279 - 289
  • [45] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wang, Xuemei
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Lerner, Susan
    Kantarjian, Hagop
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2085 - 2093
  • [46] Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia
    Herold, Tobias
    Seiler, Till
    Egensperger, Rupert
    Trumm, Christoph
    Bergmann, Manuela
    Franke, Daniel
    Mumm, Friederike F. H.
    Schinwald, Nicole
    Buske, Christian
    Dreyling, Martin
    LEUKEMIA & LYMPHOMA, 2012, 53 (01) : 169 - 172
  • [47] A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
    Izutsu, Koji
    Kinoshita, Tomohiro
    Takizawa, Jun
    Fukuhara, Suguru
    Yamamoto, Go
    Ohashi, Yasuo
    Suzumiya, Junji
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 408 - 415
  • [48] Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia
    Simkovic, Martin
    Vodarek, Pavel
    Motyckova, Monika
    ecsiova, Dominika
    Rozsivalova, Petra
    Mocikova, Heidi
    Stepankova, Pavla
    Sykorova, Alice
    Hrochova, Katerina
    Vrbacky, Filip
    Belada, David
    Zak, Pavel
    Smolej, Lukas
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [49] A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
    Reynolds, Craig
    Di Bella, Nicholas
    Lyons, Roger M.
    Hyman, William
    Richards, Donald A.
    Robbins, Gerald J.
    Vellek, Mark
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1232 - 1240
  • [50] A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
    Craig Reynolds
    Nicholas Di Bella
    Roger M. Lyons
    William Hyman
    Donald A. Richards
    Gerald J. Robbins
    Mark Vellek
    Kristi A. Boehm
    Feng Zhan
    Lina Asmar
    Investigational New Drugs, 2012, 30 : 1232 - 1240
12345